Clinical Response of CD19 CAR-T Cells (relmacabtagene autoleucel, relma-cel) in Adults with Heavily-Pre-Treated Relapsed/Refractory (r/r) Large B-Cell Lymphoma in China

Currently, no CAR-T product has been approved for use in China despite having hundreds of active CAR-T trials. Relma-cel (JWCAR029) is a CAR-T product with a CAR construct comprised of a binding domain, derived from a murine CD19-specific mAb (FMC63), a CD3ζ activation domain, and a 4-1BB costimulat...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Blood 2020-11, Vol.136 (Supplement 1), p.39-40
Hauptverfasser:	Zhu, Jun, Ying, Zhitao, Song, Yuqin, Yang, Haiyan, Guo, Ye, Li, Wenyu, Zou, Dehui, Zhou, Daobin, Wang, Zhao, Zhang, Mingzhi, Wu, Jianqiu, Liu, Hui, Zhang, Pian, Yang, Su, Zhou, Zisong, Zheng, Hongxia
Format:	Artikel
Sprache:	eng
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!